Free Trial
→ Gold is soaring. Here’s how to get paid from it (From Investors Alley) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • Five stocks to consider instead of Denali Therapeutics.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover
The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
4.3341 of 5 stars		$14.55-2.5%N/A-5.27Buy$33.71
Ultragenyx Pharmaceutical (RARE)
4.4121 of 5 stars		$37.49-4.6%N/A-5.91Moderate Buy$88.77
Sarepta Therapeutics (SRPT)
4.7137 of 5 stars		$36.18-3.0%N/A28.94Moderate Buy$122.61
Pfizer (PFE)
4.9747 of 5 stars		$24.51-1.3%7.02%17.38Moderate Buy$29.17
Exelixis (EXEL)
4.2986 of 5 stars		$41.59-0.5%N/A23.50Hold$39.76
Moderna (MRNA)
4.5026 of 5 stars		$26.67-2.5%N/A-2.87Hold$46.61
United Therapeutics (UTHR)
4.9928 of 5 stars		$283.35-1.0%N/A12.44Moderate Buy$393.08
Biogen (BIIB)
4.731 of 5 stars		$130.65-1.3%N/A11.68Hold$188.19
Sanofi (SNY)
3.3784 of 5 stars		$49.67-2.3%3.20%19.95Buy$61.50
Eli Lilly and Company (LLY)
4.8026 of 5 stars		$818.56+0.8%0.73%69.90Moderate Buy$1,011.37
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

ACT FAST! Congress Is POURING Into This Stock
May 23, 2025

ACT FAST! Congress Is POURING Into This Stock

Lawmakers are making big trades again; Chris Markoch shares 3 big congressional buys, including one surprising pick that’s down over 30%.

Watch Video

Recent Videos

Palantir at All-Time Highs: Take Profits or Hold the Line?
3 Tech Stocks Insiders Are Buying: Speculative Plays for June
3 Defense Stocks Set to Crush the S&P This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines